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remission, symptom recurrence, or relapse, 
despite continuous antipsychotic treatment. 
This also applies to depot neuroleptic treat-
ment, which minimizes adherence problems.
Several studies suggest that with care-
ful clinical observation, substantial reduc-
tion of maintenance doses can, for many 
patients, lead to improvement in some areas 
of subjective and objective well-being and 
to a diminution of adverse effects (Kane 
et al., 1986).
Schizophrenic patients remain on antip-
sychotic (i.e., antidopaminergic) treatment 
for years, yet remarkably little is known 
about what happens to the dopamine func-
tion during ongoing treatment (Remington 
and Kapur, 2010). What is known is that in 
late stages of schizophrenia, antipsychot-
ics become inefficient frequently, despite 
chronic continuous treatment.
There is evidence from preclinical as well 
as clinical studies that point to the build up 
of dopamine supersensitivity (Samaha et al., 
2007) and tolerance to antipsychotics, lead-
ing to treatment failure over time.
IntroductIon
Talking about non-continuous antipsy-
chotic treatment in psychiatric practice in 
our time is tantamount to heresy. We have 
been perseverating in comparing psychiat-
ric illness to diabetes and hypertension so 
much that we are having a hard time fath-
oming a different analogy; perhaps, lupus, 
asthma, rheumatoid arthritis, or cancer 
in which intermittent dosing for shorter 
period of time is acceptable.
In 1960s and 1970s, there was a lot of 
talk about targeting intermittent treatment 
throughout the duration of illness, rather 
than chronic and final phase of schizophre-
nia. Widespread use of antipsychotics is his-
torically novel that only a small percentage 
phase four patients are being seen currently 
by average psychiatrists, but this number may 
grow in time. Reviewing the psychiatric lit-
erature from 1970s, it appears that continu-
ous antipsychotic exposure were not always 
necessary at that time (Prien et al., 1973).
Even in our times there are advocates of 
non-continuous treatment after the first 
episode of schizophrenia, as about 50% of 
patients have remained stable after discon-
tinuing medications in the second year of 
treatment (Harrow and Jobe, 2007). Also, 
the duration of antipsychotic treatment 
after a first episode of psychosis remains 
unclear. A comparison of evidence-based 
treatment guidelines from different coun-
tries developed on highest-quality criteria, 
yielded inconsistent recommendations 
regarding the duration of maintenance 
treatment (Gaebel et al., 2011).
tolerance to antIpsychotIc 
drugs?
Reviewing the current body of evidence, it 
appears that though the efficacy of antip-
sychotics in general is proven, a significant 
proportion of patients suffer from partial 
Neuroleptic-induced supersensitivity 
psychosis (Chouinard et al., 1978; Chouinard 
and Jones, 1980) has been observed after 
withdrawal from antipsychotic drugs such 
as quetiapine (Margolese et al., 2002), clo-
zapine (Ekblom et al., 1984; Tollefson et al., 
1999), olanzapine (Llorca et al., 2001), halo-
peridol (Kahne, 1989), and fluphenazine 
enanthate (Chouinard and Jones, 1980).
Clinical data are available to suggest 
antipsychotic tolerance with continuous 
treatment (Stip et al., 1995). The late or 
chronic stages of schizophrenia are associ-
ated with higher antipsychotic doses and 
diminished clinical response, also suggest-
ing tolerance (Remington et al., 1997; Yamin 
and Vaddadi, 2010).
Is it possible that in chronic “burn out” 
phase of schizophrenia (Figure 1) in which 
there is neuronal and synaptic loss, a targeted 
or intermittent antipsychotic treatment is 
more beneficial to the patient? In dementia, 
where there is extensive cerebral tissue loss, 
antipsychotics are being used only intermit-
tently and for a shorter duration of time.
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Figure 1 | Stages of schizophrenia. Stage 1. The patient is fully functional in early part of life, and is 
virtually asymptomatic. Stage 2. Prodromal phase starts in teens. There may be odd behaviors and subtle 
negative symptoms. Stage 3. The acute phase of the illness occurs in twenties or thirties, with positive and 
negative symptoms. Stage 4. “Burn out” phase occurs in forties or fifties with prominent negative and 
cognitive symptoms.
Sfera Intermittent treatment in chronic schizophrenia
Frontiers in Psychiatry | Molecular Psychiatry  March 2013 | Volume 4 | Article 13 | 2
acknowledgment
I would like to thank Dr. Stahl for providing 
the figure “Stages of Schizophrenia.”
references
Chouinard, G., and Jones, B. D. (1980). Neuroleptic-
induced supersensitivity psychosis: clinical and 
pharmacologic characteristics. Am. J. Psychiatry 137, 
16–21.
Chouinard, G., Jones, B. D., and Annable, L. (1978). 
Neuroleptic-induced supersensitivity psychosis. Am. 
J. Psychiatry 135, 1409–1410.
Ekblom, B., Eriksson, K., and Lindstrom, L. H. (1984). 
Supersensitivity psychosis in schizophrenic 
patients after sudden clozapine withdrawal. 
Psychopharmacology (Berl.) 83, 293–294.
Gaebel, W., Riesbeck, M., and Wobrock, T. (2011). 
Schizophrenia guidelines across the world: a selec-
tive review and comparison. Int. Rev. Psychiatry 23, 
379–387.
Harrow, M., and Jobe, T. H. (2007). Factors involved in 
outcome and recovery in schizophrenia patients not 
on antipsychotic medications: a 15-year multifollow-
up study. J. Nerv. Ment. Dis. 195, 406–414.
Ho, B. C., Andreasen, N. C., Ziebell, S., Pierson, R., and 
Magnotta, V. (2011). Long-term antipsychotic treat-
ment and brain volumes: a longitudinal study of 
first-episode schizophrenia. Arch. Gen. Psychiatry 
68, 128–137.
Kahne, G. J. (1989). Rebound psychoses following the 
discontinuation of a high potency neuroleptic. Can. 
J. Psychiatry 34, 227–229.
Kane, J. M., Woerner, M., and Sarantakos, S. (1986). Depot 
neuroleptics: a comparative review of standard, inter-
mediate, and low-dose regimens. J. Clin. Psychiatry 
47(Suppl.), 30–33.
Llorca, P. M., Vaiva, G., and Lancon, C. (2001). 
Supersensitivity psychosis in patients with schizo-
phrenia after sudden olanzapine withdrawal. Can. J. 
Psychiatry 46, 87–88.
Margolese, H. C., Chouinard, G., Beauclair, L., and 
Belanger, M. C. (2002). Therapeutic tolerance and 
rebound psychosis during quetiapine maintenance 
monotherapy in patients with schizophrenia and 
Just wondering if schizophrenic patients 
in late phases would benefit from a simi-
lar strategy. At this time, therapy using 
“as needed” antipsychotic medications is 
being discouraged in favor of continuous 
treatment, yet quite the opposite might be 
needed in this stage.
BraIn changes In long-term use 
of antIpsychotIcs
Recent data including animal studies, sug-
gests that long-term antipsychotic treat-
ment leads to global brain volume reduction 
(Ho et al., 2011).
In medicine, we are aware of many 
instances where target symptom improves 
by worsening other symptoms. Hormone 
therapy relieves menopausal symptoms 
but increases stroke risk. Non-steroidal 
anti-inflammatory drugs relieve pain, but 
increase the likelihood of duodenal ulcers 
and gastrointestinal tract bleeding. It is pos-
sible that although antipsychotics relieve 
psychosis and its attendant suffering, these 
drugs may not arrest the pathophysiologic 
processes underlying schizophrenia, and 
may even aggravate progressive brain tis-
sue volume reductions (Ho et al., 2011).
conclusIon
The last phase of schizophrenia or the 
“burn out” phase, like dementia, is charac-
terized by extensive neuronal and synaptic 
loss. Since both chronic schizophrenia and 
prolonged antipsychotic treatment result 
in cerebral tissue loss, it is appropriate to 
revisit intermittent, targeted, or “as needed” 
use of antipsychotics at this stage.
schizoaffective disorder. J. Clin. Psychopharmacol. 
22, 347–352.
Prien, R. F., Gillis, R. D., and Caffey, E. M. (1973). 
Intermittent pharmacotherapy in chronic schizo-
phrenia. Hosp. Community Psychiatry 24, 317–322.
Remington, G., and Kapur, S. (2010). Antipsychotic dos-
ing: how much but also how often? Schizophr. Bull. 
36, 900–903.
Remington, G. J., Prendergast, P., and Bezchlibnyk-Butler, 
K. Z. (1997). Neuroleptic dosing in chronic schizo-
phrenia: a 10-year follow-up. Can. J. Psychiatry 42, 
53–57.
Samaha, A., Seeman, P., Stewart, J., Rajabi, H., and 
Kapur, S. (2007). Breakthrough dopamine super-
sensitivity during ongoing antipsychotic treatment 
leads to treatment failure over time. J. Neurosci. 27, 
2979–2986.
Stip, E., Tourjman, V., Lew, V., Fabian, J., Cormier, H., 
Landry, P., et al. (1995). “Awakenings” effect with ris-
peridone. Am. J. Psychiatry 152, 1833.
Tollefson, G. D., Dellva, M. A., Mattler, C. A., Kane, J. M., 
Wirshing, D. A., and Kinon, B. J. (1999). Controlled, 
double-blind investigation of the clozapine discon-
tinuation symptoms with conversion to either olan-
zapine or placebo. The Collaborative Crossover Study 
Group. J. Clin. Psychopharmacol. 19, 435–443.
Yamin, S., and Vaddadi, K. (2010). Are we using excessive 
neuroleptics? An argument for systematic neuroleptic 
dose reduction in stable patients with schizophrenia 
with specific reference to clozapine. Int. Rev. Psychiatry 
22, 138–147.
Received: 29 September 2012; accepted: 25 February 2013; 
published online: 14 March 2013.
Citation: Sfera A (2013) Targeted intermittent treatment in 
chronic schizophrenia. Front. Psychiatry 4:13. doi: 10.3389/
fpsyt.2013.00013
This article was submitted to Frontiers in Molecular 
Psychiatry, a specialty of Frontiers in Psychiatry.
Copyright © 2013 Sfera. This is an open-access article 
distributed under the terms of the Creative Commons 
Attribution License, which permits use, distribution and 
reproduction in other forums, provided the original authors 
and source are credited and subject to any copyright notices 
concerning any third-party graphics etc.
